First line chemotherapy in advanced or metastatic NSCLC.
about
[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial.Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis.Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancerERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapyErlotinib in the treatment of advanced non-small cell lung cancer: an update for cliniciansErythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusionCopper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).[Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC.Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma.Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study.Effects of Banxia Xiexin Decoction () on cisplatin-induced apoptosis of human A549 lung cancer cells.
P2860
Q33399148-E962BA57-EE95-4623-ACA4-977CCE1D96C1Q33405558-74C4FFF7-955E-46D2-B651-6550447CC3CFQ33422985-CCCA5405-F2EA-43E2-B187-3A7C56A57628Q33532808-5778AD1B-CDB7-4E80-A526-14EB6B7FD731Q33814552-6028283F-5589-492F-BC2D-E23827EA22ADQ34243429-97B3A1A3-BFE9-4DC3-8BE9-CBF5B0480432Q35061055-48ECD198-372C-451B-AFBA-D5F9EE7358C5Q35628121-68B9C700-B997-44D4-B486-61AE3DF9068EQ35633372-E73D1E0F-D9DE-4BDC-B117-6A17BF906D20Q35812082-6C2DAD1C-4D93-4C65-ABCA-6198925D1C5BQ36378063-AAFA33B6-A7B0-482A-9759-B5505B634D5BQ37507351-DCC6154E-9EBA-48CB-8030-F4E1F71F0B2DQ37507457-A6299C99-BD69-4495-9CD9-99E51F567861Q37591935-0E5D8D3C-204C-4AD2-B7BD-E3B931CD80D9Q47094941-68B14DD3-A558-4708-A824-C54795153F61Q48457026-9382EBFF-8230-4071-9C78-0E5025F7035EQ49788473-62E53D8C-49CF-4579-9735-86FF5C04F3E2
P2860
First line chemotherapy in advanced or metastatic NSCLC.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
First line chemotherapy in advanced or metastatic NSCLC.
@ast
First line chemotherapy in advanced or metastatic NSCLC.
@en
type
label
First line chemotherapy in advanced or metastatic NSCLC.
@ast
First line chemotherapy in advanced or metastatic NSCLC.
@en
prefLabel
First line chemotherapy in advanced or metastatic NSCLC.
@ast
First line chemotherapy in advanced or metastatic NSCLC.
@en
P2093
P356
P1433
P1476
First line chemotherapy in advanced or metastatic NSCLC.
@en
P2093
P356
10.1093/ANNONC/MDJ953
P478
17 Suppl 5
P577
2006-05-01T00:00:00Z